Agios Pharmaceuticals Inc’s recently made public that its Director FOUSE JACQUALYN A unloaded Company’s shares for reported $0.19 million on Apr 10 ’25. In the deal valued at $25.90 per share,7,497 shares were sold. As a result of this transaction, FOUSE JACQUALYN A now holds 149,220 shares worth roughly $4.51 million.
Then, FOUSE JACQUALYN A bought 7,497 shares, generating $194,172 in total proceeds.
Before that, Burns James William sold 4,005 shares. Agios Pharmaceuticals Inc shares valued at $142,338 were divested by the Chief Legal Officer at a price of $35.54 per share. As a result of the transaction, Burns James William now holds 18,650 shares, worth roughly $0.56 million.
H.C. Wainwright initiated its Agios Pharmaceuticals Inc [AGIO] rating to a Buy in a research note published on February 24, 2025; the price target was $58. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Leerink Partners revised its rating on September 27, 2024. It rated AGIO as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of AGIO
On Tuesday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock jump 1.34% to $30.20. Over the last five days, the stock has gained 1.21%. Agios Pharmaceuticals Inc shares have fallen nearly -8.09% since the year began. Nevertheless, the stocks have fallen -9.69% over the past one year. While a 52-week high of $62.58 was reached on 02/24/25, a 52-week low of $23.42 was recorded on 04/09/25. SMA at 50 days reached $28.95, while 200 days put it at $38.93.
Levels Of Support And Resistance For AGIO Stock
The 24-hour chart illustrates a support level at 29.72, which if violated will result in even more drops to 29.25. On the upside, there is a resistance level at 30.65. A further resistance level may holdings at 31.11. The Relative Strength Index (RSI) on the 14-day chart is 56.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.82, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 12.80%. Stochastics %K at 82.11% indicates the stock is a selling.
The most recent change occurred on February 08, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating .
